Modified glasgow prognostic score in patients with small-cell lung cancer

Kurishima,Koichi; Watanabe,Hiroko; Ishikawa,Hiroichi; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/mco.2017.1261

Modified glasgow prognostic score in patients with small-cell lung cancer

Authors:
- Koichi Kurishima
- Hiroko Watanabe
- Hiroichi Ishikawa
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations

Affiliations: Division of Respiratory Medicine, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki 305‑8558, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Tsukuba, Ibaraki 310‑0015, Japan
Published online on: May 12, 2017 https://doi.org/10.3892/mco.2017.1261
Pages: 121-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systemic inflammatory response, which represents the presence of cachexia, is observed often in patients with lung cancer. To evaluate the prognostic significance of the presence of a systemic inflammatory response in small cell lung cancer (SCLC) patients, a retrospective study using modified Glasgow prognostic Score (mGPS) was performed. This score is composed of serum albumin and C‑reactive protein levels. All the patients with SCLC who were diagnosed in Tsukuba University Hospital, Tsukuba Medical Center Hospital and Mito Medical Center between April 1999 and July 2016 were included in this study. During the study period, 332 patients with SCLC were consecutively admitted to these hospitals. Among them, 54 (16.9%) had mGPS=1, and 73 (22.9%) had mGPS=2. Male sex, advanced stage, poor performance status and no chemotherapy were unfavorable prognostic factors in uni‑ and multivariate‑analysis. In addition, the presence of a systemic inflammatory response was confirmed as an unfavorable prognostic factor. In patients with SCLC, an existing systemic inflammatory response adversely affected the outcome. The patient's extent of disease as well as medical conditions including systemic inflammatory response must be taken into consideration when deciding whether to offer a standard therapy that may increase treatment‑associated mortality.

View Figures

View References

1	Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA and Preston T: Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 23:584–588. 1999. View Article : Google Scholar : PubMed/NCBI
2	McMillan DC, Scott HR, Watson WS, Preston T, Milroy R and McArdle CS: Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer. 31:101–105. 1998. View Article : Google Scholar : PubMed/NCBI
3	McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR and McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 39:210–213. 2001. View Article : Google Scholar : PubMed/NCBI
4	Meek CL, Wallace AM, Forrest LM and McMillan DC: The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr. 29:206–209. 2010. View Article : Google Scholar : PubMed/NCBI
5	McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67:pp. 257–262. 2008; View Article : Google Scholar : PubMed/NCBI
6	McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
7	Dowell JE: Small cell lung cancer: Are we making progress? Am J Med Sci. 339:68–76. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhou T, Hong S, Hu Z, Hou X, Huang Y, Zhao H, Liang W, Zhao Y, Fang W, Wu X, et al: A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol. 36:337–343. 2015. View Article : Google Scholar : PubMed/NCBI
9	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI
10	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
11	Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ and McMillan DC: Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg. 14:781–787. 2010. View Article : Google Scholar : PubMed/NCBI
12	Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG and McMillan DC: Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol. 18:997–1005. 2011. View Article : Google Scholar : PubMed/NCBI
13	Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W, Xie H, Qin GY and Zhao NQ: Comparison of the glasgow prognostic score (GPS) and the modified glasgow prognostic score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 142:1285–1297. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhu L, Chen S, Ma S and Zhang S: Glasgow prognostic score predicts prognosis of non-small cell lung cancer: A meta-analysis. Springerplus. 5:4392016. View Article : Google Scholar : PubMed/NCBI
15	Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y and Fearon KC: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17:519–531. 2016. View Article : Google Scholar : PubMed/NCBI
16	Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, et al: Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: Results of a randomized phase 2 trial. Support Care Cancer. 24:3495–3505. 2016. View Article : Google Scholar : PubMed/NCBI